LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
Novo Nordisk’s main competitor is the American drugmaker Eli Lilly, which also sells obesity drugs. On Wednesday, Novo Nordisk said its revenue jumped 25 percent last year to 290 billion Danish ...
With sales of Novo Nordisk’s obesity blockbuster Wegovy more than ... the drugmaker’s head of U.S. operations and global business development, noting that the GLP-1 med has reached about ...
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...
A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...
Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...
Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...
Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback